<DOC>
	<DOCNO>NCT00820547</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving bevacizumab radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study give bevacizumab together chemotherapy surgery bevacizumab radiation therapy surgery see well work treat patient inflammatory breast cancer .</brief_summary>
	<brief_title>Efficacy Tolerance Study Bevacizumab Her2- Inflammatory Breast Cancer Patients</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate complete histological response rate patient inflammatory HER2-negative breast cancer treat bevacizumab concurrent chemotherapy follow bevacizumab concurrent hormonal therapy surgery radiotherapy . Secondary - Evaluate progression-fee overall survival patient 3 5 year . - Evaluate tolerance bevacizumab patient . - Assess circulate metastatic disease , , treatment . - Assess circulate endothelial cell , , treatment . - Assess predictive factor response genomic proteomic study freeze tumor sample fluid sample ( i.e. , serum plasma ) . OUTLINE : This multicenter study . - Neoadjuvant induction therapy : - Courses 1-4 : Patients receive bevacizumab IV 30-90 minute , fluorouracil IV , epirubicin hydrochloride IV 10 minute , cyclophosphamide IV 5 minute day 1 . - Courses 5-8 : Patients receive bevacizumab IV 30-90 minute docetaxel IV 1 hour day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Surgery : Patients undergo surgery 4-6 week completion bevacizumab . - Adjuvant therapy : Beginning 2-4 week surgery , patient undergo radiotherapy 6 week . Patients also receive bevacizumab IV 30-90 minute begin 2-4 week surgery , radiotherapy period . Treatment bevacizumab repeat every 3 week 30 week absence disease progression unacceptable toxicity . Patients estrogen receptor- progesterone receptor-positive ( ≥ 10 % IHC ) receive follow concurrent hormonal therapy begin week 7 : - Premenopausal patient : Patients receive tamoxifen citrate 5 year . - Postmenopausal patient : Patients receive aromatase-inhibitor therapy ( tamoxifen citrate unable tolerate anti-aromatase therapy ) 5 year . - Perimenopausal patient : Patients receive tamoxifen citrate 2-3 year aromatase-inhibitor therapy 2-3 year OR tamoxifen citrate 5 year follow aromatase-inhibitor therapy 2-3 year ( follicle-stimulating hormone &gt; 30 IU/L and/or estradiol &lt; 30 ng/L ) . After completion study treatment , patient follow least 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm inflammatory breast cancer , meet 1 follow stag criterion : T4d , N ( AJCC stage IIIB IIIC ) GustaveRoussy Institute ( IGR ) classification Poussee evolutirie ( PEV ; measure tumor growth time ) 2 PEV 2 : tumor underlie breast tissue , especially skin , affected subacute inflammation edema involve &lt; ½ breast surface IGR classification PEV 3 PEV 3 : acute subacute inflammation edema involve &gt; ½ breast surface Biopsyconfirmed presence tumor embolism surface lymph node HER2negative ( HER2 0 1+ , HER2 2+ IHC FISHnegative allow ) No metastatic disease No noninflammatory breast cancer edema , ulceration , satellite skin nodules No bilateral breast cancer Hormone receptor status know PATIENT CHARACTERISTICS : Any menopausal status allow WHO performance status 02 Life expectancy ≥ 3 month LVEF normal ECHO ANC &gt; 1.5 x 10^9/L Platelet count &gt; 100 x 10^9/L INR ≤ 1.5 ( except patient prophylactic anticoagulant ) aPTT ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin normal SGOT SGPT ≤ 1.25 time ULN Alkaline phosphatase ≤ 2.5 time ULN Creatinine clearance ≥ 60 mL/min Proteinuria &lt; 2+ 24hour urine protein ≤ 1 g No unhealed wound , stomach ulcer , bone fracture No history thrombotic hemorrhagic disorder No significant cardiovascular disease include follow : Cerebrovascular accident within past 6 month Unstable angina Cardiac failure Myocardial infarction Arrhythmia require treatment No uncontrolled hypertension ( i.e. , systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg ) No active infection serious illness would preclude patient receive study treatment No hypersensitivity active product excipients study drug Not pregnant nursing Fertile patient must use effective contraception 6 month completion study treatment No social psychologic reason would prevent study compliance followup No patient incarcerate probation PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , hormonal therapy disease More 4 week since prior surgery ( diagnostic biopsy installation implant allow ) More 10 day since prior chronic noninflammatory steroid ( e.g. , acetylsalicylic acid &gt; 325 mg/day ) platelet anticoagulation treatment ( e.g. , dipyridamole , ticlopidine , clodiprogel , cilostazol ) More 10 day since prior oral parenteral anticoagulant thrombolytic drug ( preventative thrombolytic drug allow ) No concurrent participation another experimental clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
</DOC>